Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective hypoglycemic agents for type 2 diabetes mellitus (T2DM). It was reported that T2DM was implicated in pancreatic β-cell senescence. Whether loxenatide regulates cellular senescence of pancreatic β-cells is to be investigated. Our results revealed that high glucose (HG)-induced cellular senescence and elevated expression of SASP factors inhibited cell proliferation and stimulated DNA damage, which were reversed by loxenatide treatment. In addition, HG induction resulted in promoted insulin secretion and insulin synthesis of pancreatic β-cells and loxenatide treatment further strengthened these influences. In addition, loxenatide could inactivate the PERK/eIF2α signaling pathway via decreasing the levels of p-PERK and p-eIF2α in HG-induced pancreatic β-cells. Furthermore, CCT020312, an activator of the PERK/eIF2α signaling pathway, abolished loxenatide-mediated inhibiting cellular senescence, elevating cell proliferation and improving DNA damage and enhancing insulin secretion of HG-induced pancreatic β-cells. In conclusion, our results indicated that loxenatide impeded cellular senescence, promoted cell proliferation, improved DNA damage, enhanced insulin secretion and insulin synthesis of HG-induced pancreatic β-cells through modulating the PERK/eIF2α signaling pathway.

Keywords

loxenatide - cellular senescence - insulin secretion - the PERK/eIF2α signaling pathway - type 2 diabetes mellitus

Publication History

Received: 27 February 2024

Accepted after revision: 29 August 2024

Article published online:
27 September 2024

• References

• 1 Tudurí E, Soriano S, Almagro L. et al. The pancreatic β-cell in ageing: Implications in age-related diabetes. Ageing Res Rev 2022; 80: 101674
• 2 Galicia-Garcia U, Benito-Vicente A, Jebari S. et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020; 21: 6275
• 3 Iwasaki K, Abarca C, Aguayo-Mazzucato C. Regulation of cellular senescence in type 2 diabetes mellitus: from mechanisms to clinical applications. Diabetes Metab J 2023; 47: 441-453
• 4 Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine 2017; 21: 21-28
• 5 Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med 2020; 288: 518-536
• 6 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705
• 7 Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411
• 8 Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27: 740-756
• 9 Vidal J. Lixisenatide – a new glucagon-like peptide 1 receptor agonist in the treatment of type 2 diabetes. Eur Endocrinol 2013; 9: 76-81
• 10 [Anonymous]. Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568. Drugs R D 2004; 5: 35–40
• 11 Athauda D, Maclagan K, Skene SS. et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 1664-1675
• 12 Zhou B, Zissimopoulos J, Nadeem H. et al. Association between exenatide use and incidence of Alzheimer's disease. Alzheimers Dement (N Y) 2021; 7: e12139
• 13 Pu Z, Yang Y, Qin S. et al. The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage. Front Biosci (Landmark Ed) 2023; 28: 259
• 14 Chen H, Li XZ, Chen JQ. et al. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: a network meta-analysis. Medicine (Baltimore) 2023; 102: e34122
• 15 Lee JH, Lee J. Endoplasmic Reticulum (ER) stress and its role in pancreatic β-cell dysfunction and senescence in type 2 diabetes. Int J Mol Sci 2022; 23: 4843
• 16 Gao H, Yan P, Zhang S. et al. Chronic alpha-linolenic acid treatment alleviates age-associated neuropathology: roles of PERK/eIF2α signaling pathway. Brain Behav Immun 2016; 57: 314-325
• 17 Xu Q, Fu Q, Li Z. et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nat Metab 2021; 3: 1706-1726
• 18 Roger L, Tomas F, Gire V. Mechanisms and regulation of cellular senescence. Int J Mol Sci 2021; 22: 13173
• 19 Wallner EI, Wada J, Tramonti G. et al. Status of glucose transporters in the mammalian kidney and renal development. Ren Fail 2001; 23: 301-310
• 20 Alemán-González-Duhart D, Álvarez-Almazán S, Valdes M. et al. In vivo and ex vivo evaluation of 1,3-thiazolidine-2,4-dione derivatives as euglycemic agents. PPAR Res 2021; 2020: 5100531
• 21 Douros A, Yin H, Yu OHY. et al. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care 2017; 40: 1506-1513
• 22 Salpeter S, Greyber E, Pasternak G. et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2003 2. Cd002967
• 23 Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract 2010; 64: 1402-1414
• 24 Cai H, Chen Q, Duan Y. et al. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. Front Endocrinol (Lausanne) 2023; 14: 1106868
• 25 Zhang S, Zhang C, Chen J. et al. Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial. Front Pharmacol 2023; 14: 1171399
• 26 Murakami T, Inagaki N, Kondoh H. Cellular senescence in diabetes mellitus: distinct senotherapeutic strategies for adipose tissue and pancreatic β cells. Front Endocrinol (Lausanne) 2022; 13: 869414
• 27 Chen SD, Chuang YC, Lin TK. et al. Alternative role of glucagon-like peptide-1 receptor agonists in neurodegenerative diseases. Eur J Pharmacol 2023; 938: 175439
• 28 Hou Y, Dan X, Babbar M. et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019; 15: 565-581
• 29 Irwin N, McClean PL, Harriott P. et al. Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. Exp Gerontol 2007; 42: 296-300
• 30 Katayama T, Imaizumi K, Sato N. et al. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol 1999; 1: 479-485
• 31 Kedi X, Ming Y, Yongping W. et al. Free cholesterol overloading induced smooth muscle cells death and activated both ER- and mitochondrial-dependent death pathway. Atherosclerosis 2009; 207: 123-130
• 32 Ozcan U, Cao Q, Yilmaz E. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461
• 33 Wang Y, Wu D, Li D. et al. The role of PERK-eIF2〈-ATF4-CHOP pathway in sevoflurane induced neuroapoptosis and cognitive dysfunction in aged mice. Cell Signal 2023; 110: 110841
• 34 Zhao H, Ma N, Liu Z. et al. Protective effect of Wuzi Yanzong recipe on testicular dysfunction through inhibition of germ cell apoptosis in ageing rats via endoplasmic reticulum stress. Andrologia 2019; 51: e13181
• 35 Leclerc I, Rutter GA. AMP-activated protein kinase: a new beta-cell glucose sensor?: Regulation by amino acids and calcium ions. Diabetes 2004; 53: S67-S74
• 36 Shibasaki T, Takahashi T, Takahashi H. et al. Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Diabetes Obes Metab 2014; 16: 118-125